Navigation Links
Hearing-loss-prevention drugs closer to reality thanks to new UF test

GAINESVILLE, Fla. A new way to test anti-hearing-loss drugs in people could help land those medicines on pharmacy shelves sooner. University of Florida researchers have figured out the longstanding problem of how to safely create temporary, reversible hearing loss in order to see how well the drugs work. The findings are described in the November/December 2012 issue of the journal Ear & Hearing.

"There's a real need for drug solutions to hearing loss," said lead investigator Colleen Le Prell, Ph.D., an associate professor in the department of speech, language, and hearing sciences at the UF College of Public Health and Health Professions. "Right now the only options for protecting against noise-induced hearing loss are to turn down what you're listening to, walk away from it or wear ear plugs, and those options may not be practical for everyone, particularly for those in the military who need to be able to hear threats."

About 26 million American adults have noise-induced hearing loss, according to the National Institute on Deafness and Other Communication Disorders. Prevention is key because damage to hearing-related hair cells in the inner ear by loud noise is irreversible. Though hearing aids can help amplify sound and implanted devices can restore some sensation of sound for those with more profound hearing loss, they do not restore normal hearing. Thus, researchers are trying to find drugs that prevent hearing damage in the first place.

Although prototype drugs have prevented noise-induced hearing loss in laboratory animals, it has been hard to know whether the same protection is possible in humans, largely because researchers lacked an effective method for the needed tests. Those tests are now achievable because of the UF efforts. The work brings scientists closer to the development of drugs that could help protect people at risk of hearing damage from rock concert goers to factory workers and military personnel who are routinely exposed to noise as they work.

Le Prell's model is the first to use controlled music levels to reliably cause low-level, temporary hearing loss in human participants. Other studies have used beeps or tones, user-selected music levels, or music exposures that don't result in temporary hearing loss. Three monitoring boards ensured that studies of the UF model met national safety standards for research in humans. Co-investigator Patrick Antonelli, M.D., the George T. Singleton Professor and chair of the UF department of otolaryngology, provided onsite supervision of study participant safety, and collaborators at the University of Michigan and Southern Illinois University were involved in study design and safety discussions.

"Dr. Le Prell started with a unique idea to create a reversible noise-induced hearing loss and has established solid groundwork for this new model in the use of clinical drug testing," said hearing expert Jianxin Bao, Ph.D., an associate professor of otolaryngology and biology and biomedical sciences at Washington University School of Medicine in St. Louis, who was not involved in the UF study. "As for every new model, several unknown factors exist for this elegant experiment model, which requires further detailed studies."

To induce temporary hearing loss, study participants listened to rock or pop music on a digital music player via headphones for four hours at sound levels ranging from 93 decibels the noise level of a power lawn mower to 102 decibels, the noise of a jackhammer. Each participant got a hearing test four times, 15 minutes to three-and-a-quarter hours after his or her listening session, as well as follow-up tests one day and one week later. Fifteen minutes after the music stopped, those who listened to the highest music levels had lost just a small amount of hearing six decibels, on average. Hearing returned to normal within three hours.

Le Prell's group will use this testing model in two first-of-a-kind clinical trials of therapeutics designed to determine if noise-induced hearing loss can be prevented in humans. The first study uses a dietary supplement called Soundbites, manufactured by Hearing Health Science, a University of Michigan bioscience spinoff company. Soundbites contains the vitamin A precursor beta carotene, vitamins C and E and the mineral magnesium. This antioxidant formula, the patent for which Le Prell shares, has prevented temporary and permanent hearing loss in laboratory animals.

In the other ongoing study, participants take a drug called SPI-1005 produced by Sound Pharmaceuticals Inc. The test capsule contains a new molecule called ebselen that mimics a protective inner ear protein.

The Food and Drug Administration will monitor the studies to ensure openness, analytical rigor and participant safety as the researchers try to get badly needed drugs onto the market.

"We really want to find out what's going to work and we want to make it possible for strategies that do work to get in the hands of the people who need them," Le Prell said.


Contact: Jill Pease
University of Florida

Related medicine news :

1. Scientists find a new way to boost common cancer drugs
2. UGA discovery promises to improve drugs used to fight cancer, other diseases
3. Which Hospital Patients Need Drugs to Prevent Gastrointestinal Bleeding?
4. Helping patients navigate new cancer drugs
5. 1/3 of Docs Often Prescribe Brand-Name Drugs Over Generics: Study
6. Common Blood Pressure Drugs Might Lower Dementia Risk
7. Fake Drugs Entering the U.S.: Lawyers at Console & Hollawell Highlight Federal Warnings About Counterfeit Medications
8. Penn team developing new class of malaria drugs using essential calcium enzyme
9. Patient Survival Rises When Drugs Suppress Hepatitis C in Blood: Study
10. Options increase for CML patients failed by existing drugs
11. Targeted gene silencing drugs are more than 500 times more effective with new delivery method
Post Your Comments:
Related Image:
Hearing-loss-prevention drugs closer to reality thanks to new UF test
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
(Date:11/27/2015)... ... ... Herpes-only dating community in the world, revealed that over 50% of its members are under ... under the age of 50 – or 67% of the population - are infected with ... infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of the ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in America", ... delves into an array of issues that are presently affecting Americans. Dedicated to providing ... this show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College ... Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD ... colleges, as only one of twelve colleges and universities in the state of California ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology: